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The heterogeneity and instability of human
tumors hamper straightforward identification
of cancer-causing mutations through genomic
approaches alone. Herein we describe a mouse
model of liver cancer initiated from progenitor
cells harboring defined cancer-predisposing
lesions. Genome-wide analyses of tumors in
this mouse model and in human hepatocellular
carcinomas revealed a recurrent amplification
at mouse chromosome 9qA1, the syntenic re-
gion of human chromosome 11q22. Gene-ex-
pression analyses delineated cIAP1, a known
inhibitor of apoptosis, and Yap, a transcription
factor, as candidate oncogenes in the amplicon.
In thegenetic context of their amplification, both
cIAP1 and Yap accelerated tumorigenesis and
were required to sustain rapid growth of ampli-
con-containing tumors. Furthermore, cIAP1 and
Yap cooperated to promote tumorigenesis.
Our results establish a tractable model of liver
cancer, identify two oncogenes that cooperate
by virtue of their coamplification in the same ge-
nomic locus, and suggest an efficient strategy
for the annotation of human cancer genes.
INTRODUCTION
Tumorigenesis results from a progressive sequence of
genetic and epigenetic alterations that promote the malig-
nant transformation of the cell by disrupting key processes
involved in normal growth control and tissue homeostasis(Hanahan and Weinberg, 2000). Since complex signaling
networks control these processes, mutations in many
genes can provide the cell with a specific aberrant capabil-
ity. Consequently, the combination of genetic alterations
that can occur during tumor evolution is enormous, per-
haps underpinning the substantial heterogeneity in tumor
behavior that occurs even within a particular tumor type.
In addition, genomic instability is a common, if not univer-
sal, feature of advanced tumors. This instability provides
tumor cells with the ability to adapt to new environments
but may also increase the rate of bystander mutations
that do not contribute to the malignant phenotype.
The completion of the human genome project has en-
abled new approaches for studying cancer genetics and
cancer genomes. For example, gene-expression profiling
usingmicroarrays has improved the classification of some
tumor types (Segal et al., 2005). Moreover, DNA rese-
quencing has identified unanticipated mutations in onco-
genes such as BRAF and EGFR, thus suggesting new
drug targets or therapeutic strategies (Davies et al., 2002;
Lynch et al., 2004). Finally, genome scanning for gene
copy-number alterations has identified many loci harbor-
ing candidate cancer genes (Kallioniemi et al., 1993;
Lucito et al., 2003). Because of these advances, efforts
to catalog all of the mutational events that contribute to
human cancer can now be envisioned. Nevertheless, for
such information to be efficiently translated into improve-
ments in cancer diagnosis and therapy, cancer-causing
mutations must be distinguished from irrelevant alter-
ations linked to complex cancer genotypes. Furthermore,
without in vivo validation, there is little stimulus for thera-
peutic development efforts. Integrative strategies to iden-
tify and validate genes with functional relevance for tumor
initiation and progression are clearly needed.
Hepatocellular carcinoma (HCC) represents a tumor type
where a more complete understanding of the underlyingCell 125, 1253–1267, June 30, 2006 ª2006 Elsevier Inc. 1253
genetics could have a major impact on treatment of the
disease. HCC is the fifth most frequent neoplasm world-
wide but, owing to the lack of effective treatment options,
represents the third leading cause of cancer death (Parkin
et al., 2001). The only curative treatments for HCC are sur-
gical resection or liver transplantation, but most patients
present with advanced disease and are not candidates
for surgery. To date, systemic chemotherapeutic treat-
ment is ineffective against HCC, and no single drug or
drug combination prolongs survival (Llovet et al., 2003).
The development of HCC is invariably associated with
liver damage caused by chronic hepatitis, extensive alco-
hol intake, or toxins, sequentially resulting in liver cirrhosis,
dysplastic lesions, and finally invasive liver carcinoma. Re-
cent studies suggest that these agents can target liver
progenitor cells (‘‘oval cells’’ in rodents and ‘‘hepatic pro-
genitor cells’’ in humans), leading to their expansion and
transformation (for review, see Alison and Lovell, 2005).
One key target in liver carcinogenesis is p53, which is
functionally attenuated by hepatitis B virus X protein
(Wang et al., 1994) and is a mutational target of aflatoxin
B1 (Aguilar et al., 1994). Other established lesions in liver
cancer include activation of the c-myc, CCND1 (cyclin
D1), or c-met oncogenes, as well as mutations in compo-
nents of the Ras/PI3 kinase pathways (Lee et al., 2005;
Feitelson et al., 2002; Suzuki et al., 1994). Still, the molec-
ular genetics of liver cancer, and how specific lesions
interact to produce its aggressive characteristics, remain
poorly understood.
Mouse models of human cancer provide powerful tools
to investigate cancer biology, genetics, and therapy. Here
we used a flexible mouse model of hepatocellular carci-
noma to search for spontaneous mutations arising in tu-
mors initiated by different oncogenic lesions and then
compared these to alterations observed in human can-
cers. This approach enabled us to pinpoint ‘‘driver genes’’
that might contribute to human liver carcinogenesis and,
using our model, to validate these changes in an appropri-
ate in vivo context. Consequently, our study not only iden-
tified two oncogenes in the same focal amplification that
cooperate during tumorigenesis but, more broadly, high-
lights the utility of integrating mouse models and cancer
genomics for the functional annotation of cancer genes.
RESULTS
Generation and Transplantation of Genetically
Altered Liver Progenitor Cells
Mostmousemodels for liver cancer are based on germline
transgenic approaches that direct expression of an onco-
gene to the liver using a tissue-specific promoter (Sandg-
ren et al., 1989; Murakami et al., 1993). Although these
models continue to provide important insights into the
pathogenesis of liver cancer, they express the oncogene
throughout the entire liver, a situation that is distinct from
spontaneous tumorigenesis. Moreover, incorporation of
additional lesions, such as a second oncogene or loss
of a tumor suppressor, requires genetic crosses that are1254 Cell 125, 1253–1267, June 30, 2006 ª2006 Elsevier Inc.time consuming and expensive. Finally, traditional trans-
genic and knockout strategies do not specifically target
liver progenitor cells, one proposed ‘‘cell of origin’’ of the
disease (Alison and Lovell, 2005).
Based on our previous work in the hematopoietic sys-
tem (e.g., Schmitt et al., 2002), we reasoned that the study
of genetic interactions in liver tumorigenesis would be fa-
cilitated by ex vivo genetic manipulation of liver progeni-
tors followed by their retransplantation into the livers of re-
cipient mice (Figure 1A). Embryonic hepatoblasts express
high E-cadherin levels, enabling these cells to be isolated
to high purity from E12.5–15 fetal livers using magnetic
bead selection (Nitou et al., 2002). These cells also ex-
pressed markers characteristic of bipotential oval cells
(see Figure S1A in the Supplemental Data available with
this article online), one presumed target of transformation
in the adult liver (Alison and Lovell, 2005). Although they
proliferated poorly in initial experiments, the introduction
of defined medium (Block et al., 1996), feeder layers,
and gelatin-coated plates to the culture conditions en-
abled the hepatoblasts to be expanded without loss of
their defining characteristics (data not shown). These con-
ditions also allowed efficient gene transfer using MSCV-
based retroviral vectors expressing green fluorescent pro-
tein (GFP) (Figure S1B) or short-hairpin RNAs (shRNAs)
capable of suppressing gene expression through RNA in-
terference (Zender et al., 2006).
To determine whether genetically modified hepato-
blasts could colonize recipient livers, we used a protocol
that optimizes engraftment of transplanted cells (Guo
et al., 2002). Animals were pretreated with retrorsine, an
alkaloid that exerts a strong and persistent block of native
hepatocyte proliferation and increases the competitive
advantage of transplanted cells (Laconi et al., 1998). Ten
days after the last retrorsine treatment, 2 3 106 GFP-
tagged E-cadherin+ liver progenitor cells were delivered
to the liver by intrasplenic injection. Oneweek later, immu-
nohistochemical analysis of liver sections revealed that
approximately one percent of the host liver consisted of
‘‘seeded’’ GFP-positive cells that were embedded within
the normal liver architecture (Figure 1B).
Generation of Liver Carcinomas from Transplanted
Liver Progenitor Cells that Resemble Human HCC
We next tested whether this approach could produce liver
carcinomas in situ. Owing to the importance of p53 inacti-
vation in this disease,we isolated hepatoblasts fromp53/
fetal livers and transduced these cells with retroviruses co-
expressingmyc (c-myc), activatedAkt (Akt1), or oncogenic
Ras (H-RasV12) (each of which affects signaling pathways
altered in human liver cancer) and GFP. As above, these
transduced cell populations were transplanted into retro-
rsine-treated mice. To further facilitate expansion of the
transplanted cells, recipient mice were treated with CCl4
(Guo et al., 2002) andmonitored for signs of disease by ab-
dominal palpation and whole-body fluorescence imaging.
Although p53/ hepatoblasts were not tumorigenic dur-
ing the analysis period, each of the cell populations that
Figure 1. Development and Character-
ization of a Genetically Tractable, Trans-
plantable Mouse Model of HCC
(A) Schematic diagram showing the generation
of in situ liver carcinomas following retroviral
transduction of purified E-cadherin+ hepato-
blasts (see Figure S1).
(B) Analysis of liver sections from mice seeded
with GFP-expressing hepatoblasts 1 week
postreconstitution. Left, H&E; middle, anti-
GFP immunofluorescence; right, DAPI.
(C) External GFP tumor imaging (top panels) or
direct imaging of the respective explanted tu-
mor-bearing livers (bottom panels) of mice re-
constituted with p53/ hepatoblasts trans-
duced with the indicated oncogene.
(D) Survival curves of mice after intrahepatic
seeding of p53/ liver progenitor cells trans-
duced with the indicated oncogene or control
vector.
(E) Explanted murine liver carcinomas (p53/;
myc) were grown briefly in culture and then di-
rectly injected into the left liver lobe. Shown is
a GFP-expressing (left) in situ tumor (right) 42
days postinjection.also expressed an oncogene eventually produced GFP-
positive tumors in the liversof recipientmice (Figure1C, top).
Gross pathological analysis of explanted livers revealed
that Myc-expressing tumors differ significantly from those
expressing Akt or Ras (Figure 1C, bottom). First, Myc-ex-
pressing tumors grow primarily as unilocular tumors,
whereas Akt- and Ras-derived tumors show aggressive,
multilocular, and infiltrative intrahepatic growth. Second,
the intrinsic tumorigenicity of p53/ liver progenitor cells
expressing Myc was significantly lower than those ex-
pressing Akt or Ras (Figure 1D). Of note, p53 loss clearlycontributed to tumorigenesis since tumors arising in
mice reconstituted with p53+/ hepatoblasts showed fur-
ther delayed tumor onset and loss of the wild-type p53 al-
lele (Figure S1D). In most instances, GFP-positive cells
derived from established tumors could be grown in culture
and subsequently formed secondary tumors upon subcu-
taneous injection into immunocompromised mice (data
not shown) or direct intrahepatic injection into syngeneic
recipients (Figure 1E).
An experienced liver pathologist (P.F.) examined the he-
matoxylin and eosin (H&E) stained sections derived fromCell 125, 1253–1267, June 30, 2006 ª2006 Elsevier Inc. 1255
Figure 2. Murine Liver Carcinomas De-
rived from E-Cadherin+ Liver Progenitor
Cells Histopathologically Resemble
Human HCC
(A) H&E-stained sections of human HCC with
the indicated histopathological variegation
(left panels) shown adjacent to corresponding
histopathologies in murine liver cancers arising
from p53/;myc hepatoblasts (center panels).
Anti-CK8 immunohistochemistry of the murine
tumors is shown at right.
(B) H&E staining of in situ and subcutaneously
retransplanted HCCs derived from p53/;myc
hepatoblasts.Myc-induced murine hepatomas (Figure 2A) and classi-
fied most as moderately well to poorly differentiated
HCCs with a mostly solid, sometimes mixed solid/trabec-
ular growth pattern. A smaller proportion of tumors dis-
played growth patterns resembling trabecular or pseudo-
glandular HCC. All tumors examined stained positive for
cytokeratin 8, confirming their liver origin. However, de-
spite their derivation from cytokeratin 19-positive liver
progenitor cells, most HCCs lost thismarker during tumor-
igenesis (Figure S1C). The tumors also expressed high
albumin levels and, similar to the situation in human
HCC, about half were positive for a-fetoprotein. Most
also expressed moderate levels of vimentin (Figure S1C),
a marker linked to aggressive tumor behavior (Hu et al.,
2004). Transplanted hepatomas retained their HCC histol-
ogy when injected orthotopically into the liver or subcuta-
neously into immunocompromised mice (Figure 2B).
Therefore, ex vivo-manipulated liver progenitor cells can
produce tumors that recapitulate the histopathology of
human HCC.
ROMA Identifies Spontaneous Mutations in a Subset
of Murine Liver Carcinomas Including a Recurrent
Amplicon at Chromosome 9qA1
To further molecularly characterize the murine HCCs de-
scribed above, we searched for spontaneously acquired
lesions in these cancers using representational oligonu-1256 Cell 125, 1253–1267, June 30, 2006 ª2006 Elsevier Inc.cleotide microarray analysis (ROMA), a genome-wide
scanning method capable of identifying copy-number
alterations in tumor cells at high resolution (Lucito et al.,
2003; B. Lakshmi, I.M. Hall, C. Egan, J. Alexander,
J. Healy, L.Z., W.X., M.S.S., S.W.L., M.W., and R.L., un-
published data). Each human or mouse ROMA array con-
sists of 85,000 oligonucleotide probes, allowing genome
scanning at a theoretical resolution of 35 kb. Although
we did not detect focal genomic alterations (<5Mb) in liver
cancers induced by Akt, a number were detected in those
initiated by Myc or Ras (Table S1). For example, a Ras-
expressing tumor harbored two focal amplifications on
chromosome 15 (Figure 3A), one containing Rnf19 and
the other containing c-myc (Figure 3B). While Rnf19 has
not been linked to tumorigenesis, c-myc alterations are
common in human liver cancer (Peng et al., 1993), and
myc cooperates with oncogenic Ras in transgenic models
of HCC (Sandgren et al., 1989). These observations under-
scored the relevance of our model and suggested that
further analyses would reveal other genes involved in
human cancer.
ROMA analysis of seven independent Myc-expressing
HCCs identified a focal amplicon on mouse chromosome
9qA1 in four of these tumors (Figures 3C and 3D; Figure S2
and Table S1). The minimal overlapping region is approx-
imately 1Mb and contains genes encoding for several ma-
trix metalloproteinases (MMPs), Yap, cIAP1 (Birc2), cIAP2
Figure 3. ROMA Identifies Focal DNA Amplifications in Murine HCCs
(A) ROMA profile of a tumor derived from p53/;Ras embryonic hepatoblasts. Data plotted are the normalized log ratio for each probe (*EST).
(B) Single-probe resolution of chromosome 15 corresponding to the tumor described in (A).
(C) Genome-wide profiles of three independent HCCs (Tu-7, Tu-9, and Tu-13) derived from p53/;myc embryonic hepatoblasts.
(D) Single-probe resolution of chromosome 9qA1 from the tumors described in (C). The minimal overlap region contains the indicated genes.(Birc3), and Porimin (Figure 3D; see Table S1 for break-
points). Amplification was confirmed by genomic qPCR
using a probe within the cIAP1 gene (data not shown). In-
terestingly, 9qA1was never found amplified inRas- orAkt-
driven liver carcinomas as assessed by either genomic
qPCR analysis or ROMA (n = 21; Table S1 and data not
shown). These observations suggest that at least one of
the genes in the 9qA1 region cooperates with myc and
p53 loss to promote hepatocarcinogenesis.
Comparative Oncogenomics Reveals Lesions in
Common between Murine and Human Cancers
In parallel to our analysis of murine HCCs, we initially con-
ducted ROMA on 25 human HCC samples. Although
these tumors contained more alterations than their murine
counterparts, using a strict cutoff of <5 Mb, we detected
copy-number alterations affecting genes previously linked
to HCC (Table S2). For example, three tumors had a chro-
mosome 11 amplification containing CCND1, two had a
chromosome 7 amplification containing c-met, two hada focal deletion on chromosome 10 containing the PTEN
tumor suppressor, and one had a deletion of chromosome
9 harboring the CDKN2A (INK4a/ARF) locus.
We also detected a focal amplification on chromosome
11q22, a region that is syntenic to the murine 9qA1 locus.
This tumor contained a c-met amplification (left peak) on
chromosome7and three sharplydelineated amplifications
on chromosome 11 (Figure 4B), includingCCND1, B0 (con-
taining no known genes), and 11q22. A second HCC har-
boring the 11q22 amplicon was identified in a set of 23
additional human HCCs (Figures S2C and S2D), as well
as in 4 of 53 human esophageal cancers (data not shown),
indicating that it occurs in gastrointestinal malignancies
derived from developmentally related organs. ROMA re-
sults were verified by genomic qPCR analysis using
probes to the cIAP1 and cIAP2 loci (data not shown).
Much like the chromosome 9 amplicon in murine HCCs,
the boundaries of the 11q22 amplicon in human HCCs
and esophageal cancers include genes encoding several
matrixmetalloproteinases,Porimin, Yap, cIAP1, and cIAP2.Cell 125, 1253–1267, June 30, 2006 ª2006 Elsevier Inc. 1257
Figure 4. ROMA Identifies Amplification of the Human Syntenic Region 11q22 in HCC and Ovarian Cancer
(A) Genome-wide profile of a human HCC harboring an amplification on chromosome 7 containing the c-met gene and three regions amplified on
chromosome 11.
(B) Single-probe resolution of chromosome 11, with genes contained within each amplicon depicted below.
(C) Genome-wide profile of an ovarian carcinoma containing the 11q22 amplification.
(D) Single-probe resolution of the 11q22 amplicon, with genes contained within the amplified region depicted below.Cross-Species Expression Analysis of Genes
from the Human and Mouse Amplicons Reveals
Consistent Overexpression of cIAP1 and Yap
The human 11q22 amplicon is observed in other human
cancers (e.g., Figures 4C and 4D), although no driver
gene has been decisively identified (Imoto et al., 2001;
Dai et al., 2003; Bashyam et al., 2005; Snijders et al.,
2005). While it represents only one of many low-frequency
events in these tumors and the HCCs evaluated here
(Table S2), our cross-species comparison suggests that
a gene (or genes) within this recurrent amplified region is
crucial for tumorigenesis in some genetic contexts. An es-
sential criterion for establishing whether an amplified gene
might contribute to tumorigenesis is that it be overex-
pressed in the tumors where it is amplified; we further
hypothesized this should hold across species. Therefore,
we performed a comprehensive expression analysis of
overlapping genes from the murine 9qA1 and human
11q22 amplicons.1258 Cell 125, 1253–1267, June 30, 2006 ª2006 Elsevier Inc.First, messenger RNA levels for all genes in these re-
gions were measured by real-time quantitative RT-PCR
(Figures 5A and 5C; Table S3). All amplicon-positive
mouse HCCs displayed elevated mRNA levels for the
MMPs exceptMMP7 and had high variability in maximum
expression levels (Table S3). In marked contrast, the
mRNA levels for MMP1, MMP3, MMP8, MMP12,
MMP13,MMP20, andMMP27 were below detection limit
in 25 human HCCs, including a tumor with the 11q22 am-
plicon (Table S3). However, MMP7 and MMP10 mRNAs
were moderately elevated in an 11q22-positive HCC.
Therefore, with the possible exception of MMP10, the
MMPs are not consistently overexpressed in amplicon-
positive murine and human HCCs and probably are not
responsible for the selective advantage conferred by this
genomic amplification. Furthermore, ROMA analysis on
various 11q22-positive human carcinomas identified an
ovarian carcinoma harboring an 11q22 amplicon that de-
cisively excluded all of the MMPs (Figures 4C and 4D).
Figure 5. cIAP1 and Yap Are Consistently Overexpressed in Mouse and Human Tumors Containing the 9qA1 or 11q22 Amplicon
(A) cIAP1, cIAP2, Yap, and Porimin mRNA levels in murine HCCs that contain the 9qA1 amplicon as determined by quantitative real-time RT-PCR
analysis.
(B) Protein lysates from 9qA1-positive (+) or -negative () liver cancers and adult mouse liver were immunoblotted with antibodies against cIAP1,
cIAP1/2, YAP, and Porimin. * denotes nonspecific bands. Tubulin was used as a loading control.
(C) Quantitative real-time RT-PCR analysis of cIAP1, cIAP2, Yap, and Porimin expression in human HCCs. * denotes a tumor with the 11q22 ampli-
fication. Cutoff for increased expression was >2-fold of the expression level in nonneoplastic liver (normal liver).
(D) Immunohistochemistry of an 11q22-positive (top) and -negative (bottom) human HCC using antibodies against the indicated protein.Concordantly, low-resolution technologies excluded at
least some MMPs from an 11q22 amplification in lung
cancer (Dai et al., 2003).
In contrast, cIAP1 and Yap mRNA and protein were
elevated in all mouse and human amplicon-containing
tumors examined (Figures 5A–5D). Both mRNAs were
also found to be overexpressed in some 11q22-positiveoral carcinomas (Snijders et al., 2005). Although Porimin
and cIAP2mRNAs were elevated in all amplicon-contain-
ing tumors examined, we could not detect overexpression
of either protein in 9qA1-positive mouse tumors (Figure
5B) or an 11q22-positive human tumor (Figure 5D). These
observations may be explained by reports that many
cells express Porimin mRNA without detectable proteinCell 125, 1253–1267, June 30, 2006 ª2006 Elsevier Inc. 1259
(Ma et al., 2001) and that cIAP1 promotes the ubiquityla-
tion and degradation of cIAP2 (Conze et al., 2005; Silke
et al., 2005). In fact, we observed that cIAP1 promoted
the turnover of cIAP2 in a dose-dependent manner in vitro
(Figure S3A) and showed that cIAP2 protein increases in
9qA1-positive murine HCC cells grown in the presence
of a proteasome inhibitor (Figure S3B). Based on these ag-
gregate observations, we considered cIAP1 and Yap as
the most likely candidate oncogenes in the region.
cIAP1 Has Oncogenic Properties and Is Required
for Rapid Tumor Growth
Inhibitor of apoptosis (IAP) proteins were originally identi-
fied in baculovirus because of their ability to block cell
death of infected cells (Crook et al., 1993). Overexpression
of cellular IAPs can inhibit apoptosis induced by different
stimuli (Lacasse et al., 1998). Although some IAPs bind
and inhibit caspases, their contribution to apoptosis regu-
lation and oncogenesis in mammalian cells is controver-
sial (Wright and Duckett, 2005).
A significant advantage of profiling the genomes of de-
fined murine tumors is that candidate genes can be eval-
uated in the genetic context where themutation spontane-
ously arose. Our studies identified the 9qA1 amplicon in
tumors derived from p53/ hepatoblasts expressing
Myc but not in other configurations, suggesting that these
cells would be ideal for evaluating the oncogenic proper-
ties of cIAP1. Therefore, p53/;myc liver progenitor cells
expressing cIAP1 or a control vector were produced using
retroviral-mediated gene transfer; as predicted, cIAP1
conferred a modest resistance to cell death triggered by
serum starvation or confluence (Figure 6A).
To determine whether cIAP1 could function as an onco-
gene in vivo, we injected the cells described above subcu-
taneously into nude mice to facilitate precise measure-
ment of tumor growth. cIAP1 significantly accelerated
the growth ofp53/;myc hepatoblasts (Figure 6B), reduc-
ing tumoronset timesbyhalf (24±2.3days formyc+cIAP1
versus 45 ± 12.2 days for myc + vector [p < 0.05]) and
greatly increasing tumor burden (myc + cIAP1 versus
myc + vector [p < 0.005] at 52 days). The resulting tumors
stably overexpressed full-length cIAP1 protein (Figure 6C,
compare lane 2 to lanes 8–13) and several degradation
products (Silke et al., 2005) anddisplayedahistopathology
that resembled moderately well to poorly differentiated
HCC (data not shown). Interestingly, one control tumor
that was harvested at a very small size already showed el-
evated levels of cIAP1 (Figure 6C, lane 7), consistent with a
subset of cells acquiring a spontaneous alteration that
upregulated the gene. In contrast, cIAP1 did not affect
the onset or progression of tumors expressing Akt or Ras
(Figures 6D and 6E), even though cIAP1 was efficiently ex-
pressed (Figures S4A and S4B). Thus, cIAP1 is selectively
oncogenic in the genetic context where its amplification
occurs.
To determine whether the cIAP proteins help sustain tu-
morigenesis, we next examined the impact of reducing
cIAP levels on tumor growth. We chose to suppress the1260 Cell 125, 1253–1267, June 30, 2006 ª2006 Elsevier Inc.expression of cIAP1 and cIAP2 since cIAP2 can be upre-
gulated in response to downregulation of cIAP1 (Conze
et al., 2005). shRNAs capable of suppressing cIAP1 and
cIAP2 expression by RNA interference (Figure 6F, com-
pare lanes 1 and 2) were cointroduced into outgrown
murine hepatoma cells containing or lacking the 9qA1 am-
plicon. These cells were then injected subcutaneously into
immunocompromised mice.
Tumors arising from 9qA1-positive cells expressing
cIAP1 and cIAP2 shRNAs showed a reduced growth
rate compared to controls (Figure 6G; p < 0.005 for tumor
burden ‘‘vector; vector’’ versus sh cIAP1;sh cIAP2 at day
18). Although tumor inhibition was incomplete, the effi-
ciency of cIAP knockdown was greatly reduced in the out-
grown tumors compared to the injected cells (Figure 6F,
compare lane 2 and lanes 5 and 6), implying that cells
retaining high cIAP levels were selected during tumor
expansion. These same shRNAs had no impact on the
growth of amplicon-negative tumors expressing either
Myc or oncogenic Ras (Figure 6H; Figure S4D), suggesting
that only cells selected for cIAP overexpression are sensi-
tive to cIAP inhibition and ruling out off-target effects of
these shRNAs on tumor growth (see also Figure S4C).
Therefore, the cIAP genes are required for the efficient
growth of tumors harboring the 9qA1 amplicon.
Yap Has Oncogenic Properties and Contributes
to Rapid Tumor Growth
In addition to cIAP1, Yap was also overexpressed at the
RNA and protein level in every tumor harboring the mouse
9qA1 or human 11q22 amplicon. Yap (synonyms Yap65 or
Yap1) was originally identified due to its interaction with
the Src-family kinase Yes (Sudol, 1994) and acts as a tran-
scriptional coactivator that can bind and activate Runx
and TEAD/TEF transcription factors (Yagi et al., 1999). In-
consistent with an oncogenic role, mammalian Yap also
interacts with the p53 family member p73 (Strano et al.,
2001) and potentiates apoptosis in a manner that is sup-
pressed by Akt (Basu et al., 2003). However, recent stud-
ies suggest that yorkie, the Drosophila homolog of Yap,
promotes tissue expansion as an effector of the Lats/
Warts pathway by activating cyclin E and the Drosophila
inhibitor of the apoptosis gene dIAP (Huang et al., 2005).
Interestingly, we also noted that murine tumors harboring
the 9qA1 amplicon overexpressed cyclin E (Figure 7B).
To determine whether Yap could also contribute to the
transformation of liver progenitor cells, we conducted
functional studies that paralleled our analysis of cIAP1.
p53/;myc hepatoblasts expressing Yap grew more rap-
idly than vector-infected cells (data not shown), with
a higher BrdU incorporation rate (Figure 7A). Furthermore,
Yap significantly accelerated tumor onset and progression
of p53/;myc liver progenitor cells (Figure 7C) and greatly
increased tumor burden (myc;vector versus myc;Yap at
day 40 [p < 0.005]). In contrast, Yap did not accelerate tu-
morigenesis together with activated Ras, although it did
enhance Akt-driven tumorigenesis, particularly at later
times (Figures 7D and 7E).
Figure 6. cIAP1 Enhances the Tumorigenicity of myc-Overexpressing p53/ Hepatoblasts
(A) Apoptosismeasurements (Cell Death Detection ELISAPLUS kit; Roche) from p53/ hepatoblasts double infected withmyc + cIAP1 ormyc + vector
following culture under the indicated serum conditions for 48 hr (left panel). Cells grown to confluence were cultured for another 48 hr, and cell death
was measured (right panel). Error bars represent mean ± SD (n = 3) per data point.
(B) Tumor volumemeasurements at various times following subcutaneous injection of p53/ hepatoblasts double infectedwithmyc + cIAP1 ormyc +
vector into the rear flanks of nudemice (n = 6 for each group). Shown is a representative of three independent experiments, each showing a statistical
difference between cIAP1 and control (p < 0.05). Error bars represent ±SD.
(C) Immunoblotting of tumors overexpressing myc-tagged cIAP1 (lanes 8–13) or control vector tumors (lanes 5–7) using antibodies against cIAP1.
Samples from cultured myc-tagged cIAP1-expressing hepatoblasts (M, lane 2) or vector alone (V, lane 1) and from 9qA1 amplicon-containing cells
(A+, lane 4) were analyzed for comparison. Note that myc-tagged cIAP1 migrates at 75 kDa and endogenous cIAP1 at 65 kDa. A is lysate from
amplicon-negative cells of the same genotype (p53/;myc). Tubulin was used as a loading control.
(D and E) p53/ hepatoblasts coexpressing Ras (D) or Akt (E) with cIAP1 or a control vector were monitored for tumorigenicity following subcuta-
neous injection into nude mice (n = 6 per group). Error bars represent ±SD.
(F) Immunoblotting of lysates derived from hepatoma cells outgrown from a 9qA1-positive p53/;myc tumor transduced with shRNAs targeting
cIAP1 and cIAP2 (sh 1+2) or control vectors (V) using antibodies against cIAP1.
(G and H) 9qA1-positive (G) and -negative (H) hepatoma cells expressing cIAP1/2 shRNAs or a control vector were monitored for tumor growth
following subcutaneous injection into nude mice. Error bars represent ±SD.We also tested whether Yap was required for efficient
tumor growth. Two distinct shRNAs were capable of sup-
pressing Yap expression, and, interestingly, cells express-
ing either Yap shRNA downregulated cyclin E (Figure 7F).
Despite the incomplete suppression of Yap, cells harbor-
ing the 9qA1 amplicon and expressing either Yap shRNA
showed slower tumor progression compared to controls
following injection into recipient mice (Figure 7G; p < 0.05[0.013 (shYap 2)/0.018 (shYap 1)] at day 25 postinjection).
Together, these data validate Yap as a potent oncogene.
cIAP1 and YapCooperate to Promote Tumorigenesis
As prevailing view in cancer genomics is that focal geno-
mic amplifications contain a key driver gene that is se-
lected for during tumorigenesis, it was surprising to identify
two oncogenes in the same focal amplicon. To determineCell 125, 1253–1267, June 30, 2006 ª2006 Elsevier Inc. 1261
Figure 7. Yap Confers a Proliferative Ad-
vantage, Has Oncogenic Properties, and
Is Required for Liver Tumor Progression
(A) The proliferation rates of p53/;myc hepa-
toblasts expressing Yap or a control vector
were assessed by the fraction of nuclei incor-
porating BrdU after a 1 hr pulse.
(B) Protein lysates from two 9qA1 amplicon-
positive tumors (+), two amplicon-negative tu-
mors (), and adult normal mouse liver were
immunoblotted with antibodies against Yap
and cyclin E. Tubulin was used as a loading
control. * denotes a nonspecific band in the
liver lysate.
(C–E) The tumorigenicity of p53/ liver pro-
genitor cells coexpressing the indicated onco-
gene (upper left) with a control vector or Yap
was assessed by caliper measurement follow-
ing subcutaneous injection into the rear flanks
of nude mice (n = 4 per group). Error bars rep-
resent ±SD.
(F) Protein lysates fromhepatoma cells (p53/;
myc) stably overexpressing Yap were infected
with control vector (V) or two different short-
hairpin RNAs targeting Yap (sh1 and sh2) and
were analyzed for Yap and cyclin E levels.
Tubulin was used as a loading control.
(G) Tumorigenicity of 9qA1-positive cells in-
fected with retroviral vectors expressing
shRNAs targeting Yap (sh1Yap or sh2Yap) or
control vector (n = 6 per group). Error bars
represent ±SD.whether cIAP1 and Yap might cooperate during tumori-
genesis, p53/;myc liver progenitor cells were infected
with either Yap and control vector or Yap plus cIAP1 and
assayed for their ability to form tumors in vivo. Tumors aris-
ing from p53/;myc hepatoblasts coexpressing cIAP1
and Yap grew faster than those expressing either onco-
gene alone (Figure 8A; p < 0.005 and p < 0.05 [0.011] for
cIAP1 + Yap versus cIAP1 or Yap alone, respectively).
These effects were not merely additive: At time points
when tumors expressing Yap alone were small and those
harboring cIAP1 alone were barely detectable, tumors co-
expressing Yap and cIAP1 were so large that the animals
had to be sacrificed (Figures 8A and 8B). Other gene com-
binations did not have these effects; for example, coex-
pression of cIAP2 and cIAP1 had no further impact on
tumorigenesis compared to cIAP1 alone, and the combi-
nation of Porimin with Yap appeared to even delay tumor-
igenesis (data not shown). Thus, our study establishes that
two adjacent genes from the same focal amplification can
cooperate during tumorigenesis.
DISCUSSION
A New Mouse Model of Hepatocellular Carcinoma
Here we develop and utilize a genetically tractable mouse
model of hepatocellular carcinoma that is based on the
isolation and ex vivo genetic manipulation of mouse em-1262 Cell 125, 1253–1267, June 30, 2006 ª2006 Elsevier Inc.bryonic liver progenitor cells followed by their seeding
into the livers of recipient mice. This model produces pa-
thologies that resemble human liver carcinomas and has
other features that make it amenable for studying liver
cancer biology. First, the ability to manipulate liver pro-
genitor cells—one presumed target of transformation in
hepatocarcinogenesis—ex vivo allows the rapid produc-
tion and analysis of tumors with complex genotypes with-
out the cost and effort associated with genetic intercross-
ing of cancer-prone strains. Second, the fact that the
system relies on transplantation of progenitor cells implies
that the recipient mice could also have different geno-
types, thereby facilitating studies of tumor/host interac-
tions. Third, the model uses bipotential liver progenitors
as the cancer-initiating cell, making it suitable for studying
a potential ‘‘cell of origin’’ of different primary liver can-
cers. Finally, the ability to rapidly generate pathologically
accurate liver tumors with different genotypes makes the
model an ideal preclinical system for testing new drugs
or drug combinations for HCC, a disease for which current
therapies are ineffective.
Identification and Validation of cIAP1 and Yap
as Human Oncogenes
We noted that amplifications of chromosome 9qA1 oc-
curred at a high frequency in murine tumors derived
from Myc-expressing cells, and at a lower frequency at
Figure 8. cIAP1 and Yap Synergize to Drive Tumorigenesis
(A) p53/;myc liver progenitor cells were infected with control vector, cIAP1, or Yap or coinfected with Yap + cIAP1 and then transplanted subcu-
taneously into nude mice (n = 6 per group). Error bars represent ±SD.
(B) GFP imaging of the tumors described in (A).the syntenic region of chromosome 11q22 in human liver
cancers. Although the 11q22 amplicon has been observed
in several tumor types, previous studies have not agreed
on the likely driver gene(s), in part, because validation
was lacking (Dai et al., 2003; Snijders et al., 2005;
Bashyam et al., 2005; Imoto et al., 2001). However,
through comparative oncogenomics and expression anal-
yses, we pinpointed cIAP1 and Yap as the most likely
driver genes in liver cancer; then, by returning to the
mouse model, we rapidly demonstrated the oncogenic
capacity of cIAP1 and Yap in the genetic setting where
spontaneous amplification occurred. Despite the detec-
tion of the 11q22 amplicon in only 5%–10% of human tu-
mor types examined, its association with common malig-
nancies including lung, ovarian, esophageal, and liver
carcinoma suggest that the overall contribution of cIAP1
and Yap to human cancer may be substantial.
The identification of cIAP1 as an oncogene is interesting
in light of the controversial role of IAPs in modulating apo-
ptosis in mammalian cells (Deveraux et al., 1998; Liston
et al., 2003; Salvesen and Duckett, 2002). In Drosophila,
the IAP genes are important cell death regulators, with
loss-of-function mutants displaying profound defects in
developmental and stress-induced apoptosis (Goyal
et al., 2000). In mammalian cells, a large body of work
shows that IAPs can suppress apoptosis (Lacasse et al.,
1998), although most studies observe relatively modest
effects despite overexpression in transient assays, and
mice with knockout of single IAP genes do not display
substantial apoptotic defects (Conze et al., 2005). Simi-
larly, IAP expression has been associated with various
cancer phenotypes (Wright and Duckett, 2005), but no
IAP has been decisively linked to tumorigenesis in vivo.
cIAP1 promoted murine HCC in cooperation with Myc,
an oncogene that drives proliferation but also promotes
apoptosis through both p53-dependent and -independent
mechanisms (Lowe et al., 2004). As in other cell types,
Myc sensitizes hepatoblasts to diverse proapoptotic sig-nals, and dampening of such signals is linked to tumori-
genesis in other contexts. In our system, the effects of
cIAP1 appeared more pronounced in vivo, suggesting
that microenvironmental effects associated with tumor
expansion may be critical for its prosurvival activities. Per-
haps this explains the variable effects of cIAP1 observed
in previous in vitro studies; alternatively, nonapoptotic
cIAP1 activities may contribute to its oncogenic role. In
any case, the antiapoptotic activity of cIAP1 would be un-
likely to cooperate with Akt or Ras, which already transmit
prosurvival signals (Lowe et al., 2004).
The finding that Yap is also an oncogene in the 9qA1/
11q22 amplicon is surprising considering its ability to po-
tentiate the proapoptotic functions of p73, a p53 family
member (Basu et al., 2003). However, yorkie (yki), the
Drosophila homolog of mammalian Yap, links warts/large
tumor suppressor (wts/lats) signaling and transcriptional
regulation in the Hippo (hpo) pathway (Huang et al.,
2005). This pathway also includes the genes salvador
(sav),mobas tumor suppressor (mats),NF2/Merlin, andex-
panded (Hamaratoglu et al., 2006; Edgar, 2006) and func-
tions to precisely control tissue expansion by coordinately
regulating cell proliferation and cell death. This is ultimately
achieved through transcriptional regulation of cyclin E and
the Drosophila inhibitor of apoptosis protein, dIAP.
Interestingly, mammalian homologs exist for most
Hippo pathway members (Chan et al., 2005; Tamaskovic
et al., 2003), some of which have previously been linked
to cancer development (e.g., Lats2 and NF2) (St John
et al., 1999; Takahashi et al., 2005; McClatchey and Gio-
vannini, 2005). In addition,Drosophilamutants can be res-
cued by the human homologs for Yap, LATS1, MATS1,
and MSTS2. Interestingly, although Yap may have addi-
tional targets inmammalian cells, we note thatmammalian
cells and tumors with high Yap levels proliferate rapidly
and have high levels of cyclin E. It is intriguing that
cIAP1—a gene with structural and functional similarity to
dIAP—resides in an adjacent chromosomal location inCell 125, 1253–1267, June 30, 2006 ª2006 Elsevier Inc. 1263
mice and humans and is coamplified with Yap in tumors.
These data demonstrate a functional conservation and
reveal the potential importance of the Hippo signaling net-
work in hepatocellular carcinoma and perhaps other can-
cers. In further support of this possibility, Yap can also
transform mammary epithelial cells in vitro (D. Haber and
J. Brugge, personal communication).
Perhaps the most remarkable observation in our study
was the demonstration that two genes embedded within
the same focal amplification cooperate in cancer develop-
ment. Thus, while cIAP1 and Yap can act independently as
oncogenes, they synergize in transforming hepatoblasts
and promoting tumorigenesis. Such codriver effects may
not be restricted to the 11q22 amplicon, as suggested in
a recent study of the 20q13.2 breast cancer amplicon,
where there is universal overexpression of two genes:
ZNF217, which is capable of immortalizing human mam-
mary epithelial cells in culture, and prefoldin 4 (PFDN4)
(Collins et al., 2001). These results underscore the com-
plexity of cancer genomes and should force a reexamina-
tion of well-characterized amplification events for the
presence of additional oncogenic lesions and potential
drug targets.
Comparative Oncogenomics to Accelerate Cancer
Genome Annotation and Target Identification
Our study took advantage of cross-species comparisons
to help prioritize candidate oncogenes and then used a rel-
evant mouse model to validate their role in tumorigenesis.
Thus, our genome-wide analysis of human HCC identified
a large number of genetic changes including the 11q22
amplicon, but the fact we detected a syntenic lesion on
chromosome 9qA1 in a specific type of murine HCC pro-
vided a filter that allowed us to prioritize this lesion for
further study. Importantly, our analysis of mouse tumors
identified an appropriate setting to study the oncogenic
potential of cIAP1 and Yap: a genetic background in which
amplification of cIAP1 and Yap spontaneously occurred.
A similar comparative genomic approach has been ap-
plied by Chin and colleagues to identify NEDD9 as a me-
tastasis-promoting gene that allows escape from tumor
cell dependence on Ras signaling (Kim et al., 2006 [this
issue of Cell]).
Moving forward, our study suggests an integrative strat-
egy to complement the Human Cancer Genome Project,
whose goal is to catalog all of the mutations that contrib-
ute to human cancer (Garber, 2005). The advantages of
using genomics to survey human tumors are obvious:
These tumors harbor changes relevant to the human dis-
ease. However, spontaneous human cancers are hetero-
geneous and can display extreme genomic instability.
Thus, it is often difficult to separate causative from pas-
senger mutations or to identify the key gene (or genes) in
a larger region of chromosomal gain or loss (Cox et al.,
2005; Futreal et al., 2005). Even with a statistically good
candidate, validation can be challenging—it is often nec-
essary to surveymany in vitro assays to link a particular le-
sion to cancer phenotypes. Furthermore, without in vivo1264 Cell 125, 1253–1267, June 30, 2006 ª2006 Elsevier Inc.validation, therapeutic development efforts are difficult
to envision.
By integrating data from human cancer genomics with
corresponding data from appropriate mouse models, it
should be possible to expeditiously focus on the cancer
lesions most likely to have translational potential. First,
identifying common lesions through cross-species com-
parisons increases confidence that these lesions will
prove important, a particularly relevant issue when study-
ing relatively low-frequency events. In fact, owing to
reduced selective pressure for multiple mutations and/or
inherent differences in telomere biology (Artandi and
Depinho, 2000), genetically defined murine tumors are
often less complex than their corresponding human coun-
terparts. Second, by incorporating murine tumors into the
analysis, it is possible to increase the sample size and ex-
ploit synteny to exclude candidates outside the region of
overlap. Third, genetically engineered mice, by definition,
develop more defined cancers than humans. Thus, the
identification of a particular lesion in murine cancers im-
mediately provides information concerning the evolution-
ary context in which it arose and identifies a relevant set-
ting in which to study its oncogenic potential. Finally,
mouse models provide excellent settings to test the suit-
ability of a cancer lesion as a therapeutic target and, at
the same time, provide ideal preclinical models for subse-
quent drug testing. We believe that such integrative ap-
proaches will speed up the pace of discovery and help
translate the promise of cancer genetics into improve-
ments in cancer diagnosis, prognosis, and therapy.
EXPERIMENTAL PROCEDURES
Generation of Genetically Defined Liver Carcinomas, Tumor
Retransplantation, Analysis, and Immunohistochemistry
Isolation, culturing, and retroviral infection of purified hepatoblasts as
well as surgical procedures, retrorsine treatment of mice, tumor mon-
itoring, and tumor retransplantation are described in the Supplemental
Experimental Procedures and Zender et al. (2006). All retroviruses
were based on MSCV vectors containing human cDNAs encoding
for myc, H-RasV12, and Akt or the murine cDNAs encoding Yap and
myc-tagged cIAP1. Short-hairpin RNAs against cIAP1, cIAP2, or Yap
were expressed from the LTR promoter of MSCV retroviruses. Tumor
volume (cm3) was calculated as length3 width3 height. Paraffin-em-
bedded liver tumor sections were stained with hematoxylin and eosin
according to standard protocols or with a-GFP (Abcam 290). Standard
Proteinase K antigen retrieval was used. Human hepatocellular carci-
nomas were analyzed using antibodies against Ck8 (RDI), cIAP1 (Silke
et al., 2005), cIAP2 (sc-7944, Santa Cruz), YAP1 (sc-15407, Santa
Cruz), and Porimin (IMG472, Imgenex).
Immunoblotting
Fresh tumor tissue or cell pellets were lysed in RIPA buffer using a tis-
sue homogenizer. Equal amounts of protein (16 mg) were separated on
10% SDS-polyacrylamide gels and transferred to PVDF membranes.
The blots were probed with antibodies against cIAP1 (Silke et al.,
2005), cIAP1/2 (gift from P. Liston; 1:2000), YAP1 (sc-15407, Santa
Cruz; 1:200), Porimin (IMG472, Imgenex; 1:300), cyclin E (#06-459, Up-
state; 1:500), tubulin (B-5-1-2, Sigma; 1:5000), vimentin (Abcam;
1:1000), cytokeratin 19 (Biocare Medical; 1:1000), albumin (Biogene-
sis; 1:5000), or AFP (Dako; 1:1000).
Cell Proliferation Assay and Cell Death ELISA
Cells plated on gelatin-coated coverslips were incubated with 5-
bromo-20-deoxyuridine (BrdU; 100 mg/ml; Sigma) for 1 hr. Nuclei incor-
porating BrdU were visualized by immunolabeling using anti-BrdU
antibody (Pharmingen; 1:400) as previously described (Narita et al.,
2003). DNA was visualized by DAPI (1 mg/ml) after permeabilization
with 0.2% Triton X-100/PBS. Cells were grown in various concentra-
tions of serum, and apoptosis was measured using the Cell Death
Detection ELISAPLUS kit (Roche).
Representational Oligonucleotide Microarray Analysis
Human tumor samples were obtained from the NCI-sponsored Coop-
erative Human Tissue Network or the tissue bank of the University of
Hong Kong. Genomic DNA was isolated from human or mouse tumors
using the PureGene DNA Isolation Kit (Gentra). Hybridizations were
carried out on 85K arrays (NimbleGen) (Lucito et al., 2003; B. Lakshmi,
I.M. Hall, C. Egan, J. Alexander, J. Healy, L.Z., W.X., M.S.S., S.W.L.,
M.W., and R.L., unpublished data). The genome position was deter-
mined from the UCSC GoldenPath browser (freezes April 2003 for hu-
man and February 2003 for mouse). Focal gains or losses were defined
as spanning <5 Mb.
Quantitative Real-Time PCR
Quantitative real-time PCRwas performed on a PRISM7700 sequence
detector (Applied Biosystems, Foster City, CA, USA). Quantification of
genomic copy number was based on standard curves derived from se-
rial dilutions of normal human genomic DNA (Invitrogen). For quantita-
tion of mRNA expression, mouse tumors were freshly homogenized in
Trizol (GIBCO). RNA was isolated and treated with RNase-free DNase
(QIAGEN) and purified over QIAGEN RNAeasy columns. Total RNA
was converted to cDNA using TaqMan reverse transcription reagents
(Applied Biosystems) and used in qPCR reactions with incorporation of
Sybr Green PCR Master Mix (Applied Biosystems) done in triplicate
using gene-specific primers. Quantification of mRNA expression of
human tumor samples was performed using TaqMan probes (Applied
Biosystems). Samples were normalized to the level of b-actin. Primer
sequences are listed in Supplemental Experimental Procedures.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, four figures, and three tables and can be
found with this article online at http://www.cell.com/cgi/content/full/
125/7/1253/DC1/.
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